News NICE recommends Bayer drug for severe short-sightedness Eylea should be funded in mCNV, says NICE
Partner Content Partner Content 5 Key Reasons Why You Should Attend Europe's Leading Ophthal... 5 Key Reasons Why You Should Attend
News Novartis next generation eye drug outperforms Eylea Brolucizumab could offer quarterly dosing schedule.
News Novartis takes aim at Shire and Allergan with dry-eye drug Swiss company takes option on Lubris' ECF843.
News Shire looks to eye drug as sales beat forecasts Company reports better than expected full year figures.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
